Duloxetine  	Duloxetine  	 NNP	B-NP
in  	in  	 IN	O
major  	major  	 JJ	O
depressed  	depressed  	 JJ	O
patients  	patients  	 NNS	O
resistant  	resistant  	 VBP	O
to  	to  	 TO	O
SSRIs  	SSRIs  	 JJ	O
and 	and 	 CC	O
/ 	/ 	 NNP	O
or  	or  	 CC	O
venlafaxine  	venlafaxine  	 JJ	O
Several  	Several  	 JJ	O
acute  	acute  	 JJ	O
depression  	depression  	 NN	B-NP
trials  	trials  	 NNS	I-NP
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
only  	only  	 RB	O
35 	35 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patients  	patients  	 NNS	O
achieve  	achieve  	 VBP	O
remission  	remission  	 JJ	B-NP
state  	state  	 NN	I-NP
with  	with  	 IN	O
antidepressant  	antidepressant  	 JJ	B-NP
monotherapy 	monotherapy 	 NN	I-NP
.  	.  	 .	O
An  	An  	 DT	O
increasing  	increasing  	 JJ	O
body  	body  	 NN	O
of  	of  	 IN	O
evidence  	evidence  	 NN	O
is  	is  	 VBZ	O
emerging  	emerging  	 VBG	O
suggesting  	suggesting  	 VBG	O
that  	that  	 IN	O
multi-action  	multi-action  	 JJ	B-NP
antidepressants  	antidepressants  	 NN	I-NP
might  	might  	 MD	O
be  	be  	 VB	O
more  	more  	 RBR	O
effective  	effective  	 JJ	O
in  	in  	 IN	O
treatment-resistant  	treatment-resistant  	 JJ	B-NP
depressed  	depressed  	 JJ	I-NP
patients  	patients  	 NNS	I-NP
than  	than  	 IN	O
single-action  	single-action  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
context 	context 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
purpose  	purpose  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	O
was  	was  	 VBD	O
to  	to  	 TO	O
assess  	assess  	 VB	O
the  	the  	 DT	O
effectiveness  	effectiveness  	 NN	O
of  	of  	 IN	O
duloxetine  	duloxetine  	 NN	B-NP
in  	in  	 IN	O
treatment-resistant  	treatment-resistant  	 JJ	B-NP
major  	major  	 JJ	I-NP
depressed  	depressed  	 JJ	I-NP
outpatients 	outpatients 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
performed  	performed  	 VBD	O
a  	a  	 DT	O
retrospective  	retrospective  	 JJ	B-NP
study  	study  	 NN	I-NP
assessing  	assessing  	 VBG	O
the  	the  	 DT	O
efficacy  	efficacy  	 NN	O
of  	of  	 IN	O
duloxetine  	duloxetine  	 NN	B-NP
in  	in  	 IN	O
major  	major  	 JJ	O
depressed  	depressed  	 JJ	O
outpatients  	outpatients  	 NNS	O
who  	who  	 WP	O
did  	did  	 VBD	O
not  	not  	 RB	O
achieve  	achieve  	 VB	O
full  	full  	 JJ	O
symptom  	symptom  	 NN	B-NP
remission  	remission  	 NNS	I-NP
( 	( 	 -LRB-	O
CGI-S  	CGI-S  	 NNP	B-NP
( 	( 	 -LRB-	O
severity 	severity 	 LS	O
)  	)  	 -RRB-	O
> 	> 	 CD	O
=3 	=3 	 CD	O
)  	)  	 -RRB-	O
after  	after  	 IN	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
adequate  	adequate  	 JJ	O
dose  	dose  	 NN	O
and  	and  	 CC	O
duration  	duration  	 NN	O
( 	( 	 -LRB-	O
more  	more  	 JJR	O
than  	than  	 IN	O
8  	8  	 CD	O
weeks 	weeks 	 NNS	O
)  	)  	 -RRB-	O
with  	with  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
either  	either  	 RB	O
one  	one  	 CD	O
SSRI  	SSRI  	 NNP	B-NP
or  	or  	 CC	O
the  	the  	 DT	O
SNRI  	SNRI  	 NNP	B-NP
venlafaxine 	venlafaxine 	 NN	I-NP
.  	.  	 .	O
We  	We  	 PRP	O
excluded  	excluded  	 VBD	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
a  	a  	 DT	O
severe  	severe  	 JJ	O
medical  	medical  	 JJ	B-NP
illness  	illness  	 NN	I-NP
and  	and  	 CC	O
a  	a  	 DT	O
personality  	personality  	 NN	B-NP
disorder 	disorder 	 NN	I-NP
.  	.  	 .	O
CGI-S  	CGI-S  	 NNP	B-NP
was  	was  	 VBD	O
used  	used  	 VBN	O
as  	as  	 IN	O
a  	a  	 DT	O
measure  	measure  	 NN	O
of  	of  	 IN	O
symptom  	symptom  	 JJ	B-NP
severity  	severity  	 NN	I-NP
and  	and  	 CC	O
administered  	administered  	 VBN	O
before  	before  	 IN	O
the  	the  	 DT	O
prescription  	prescription  	 NN	B-NP
of  	of  	 IN	I-NP
duloxetine  	duloxetine  	 NN	I-NP
and  	and  	 CC	O
6  	6  	 CD	O
weeks  	weeks  	 NNS	O
later 	later 	 RB	O
.  	.  	 .	O
The  	The  	 DT	O
sample  	sample  	 NN	O
included  	included  	 VBD	O
29  	29  	 CD	O
patients  	patients  	 NNS	O
( 	( 	 -LRB-	O
9  	9  	 CD	O
M 	M 	 NNP	O
,  	,  	 ,	O
20  	20  	 CD	O
F 	F 	 NN	O
) 	) 	 -RRB-	O
.  	.  	 .	O
We  	We  	 PRP	O
observed  	observed  	 VBD	O
a  	a  	 DT	O
very  	very  	 RB	O
significant  	significant  	 JJ	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
CGI-S  	CGI-S  	 JJ	B-NP
scores  	scores  	 NNS	I-NP
( 	( 	 -LRB-	O
4.86  	4.86  	 CD	O
±  	±  	 CD	O
0.51  	0.51  	 CD	O
to  	to  	 TO	O
2.17  	2.17  	 CD	O
±  	±  	 CD	O
1.44 	1.44 	 CD	O
,  	,  	 ,	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.0001 	0.0001 	 CD	O
)  	)  	 -RRB-	O
after  	after  	 IN	O
treatment  	treatment  	 NN	O
with  	with  	 IN	O
duloxetine  	duloxetine  	 NNS	B-NP
( 	( 	 -LRB-	O
dose  	dose  	 NN	O
between  	between  	 IN	O
60  	60  	 CD	O
and  	and  	 CC	O
120  	120  	 CD	O
mg 	mg 	 CD	B-NP
) 	) 	 -RRB-	O
.  	.  	 .	O
Remission  	Remission  	 NNP	O
was  	was  	 VBD	O
achieved  	achieved  	 VBN	O
in  	in  	 IN	O
48 	48 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
patients 	patients 	 NNS	O
.  	.  	 .	O
The  	The  	 DT	O
tolerance  	tolerance  	 NN	O
was  	was  	 VBD	O
excellent 	excellent 	 JJ	O
.  	.  	 .	O
This  	This  	 DT	O
study  	study  	 NN	O
suggests  	suggests  	 VBZ	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
interest  	interest  	 NN	I-NP
of  	of  	 IN	I-NP
duloxetine  	duloxetine  	 NN	I-NP
in  	in  	 IN	O
some  	some  	 DT	O
treatment-resistant  	treatment-resistant  	 JJ	B-NP
depressed  	depressed  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
